Patient’s perspective on pembrolizumab/lenvatinib for kidney cancer
In 2009, Cesar Fuentes was first diagnosed with kidney cancer [...]
Neoadjuvant nivolumab for patients with non-metastatic high risk kidney cancer
A recent phase 1 trial showed that treatment with nivolumab [...]
Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment
In this video interview, Dr Eric Jonasch from MD Anderson [...]
Long term follow-up of immune-related adverse events in cancer survivors
In this study carried out at a single hospital 217 [...]
ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma
In a study presented during the 2020 American Society of [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
Safety and efficacy of restarting immune checkpoint inhibitors after immune-related adverse events
Immune checkpoint inhibitors can cause a number of immune-related adverse [...]
Assessing and managing adverse events to immunotherapies
In this video interview, Brenda Martone discusses the clinical nurse [...]
IKCS 2019: Immune related adverse events
Dr Mehmet Asim Bilen of Emory University School of Medicine [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
